Stay informed about the latest Lumigen news and events.
Life Diagnostics adds a new SPARCL™ leucine-rich alpha-2-glycoprotein-1 (LRG1) assay to their lineup
Life Diagnostics, Inc. adds a new leucine-rich alpha-2-glycoprotein-1 (LRG1) assay to its extensive lineup of SPARCL assays. The new assay was developed for cats (LRG-SP-8).
Leucine-rich alpha-2-glycoprotein-1 (LRG1) is a 50 kDa protein that is primarily expressed in liver. In humans, it is a positive acute phase reactant; serum levels are elevated during chronic inflammatory diseases and infections. Research at Life Diagnostics indicates that LRG1 is also a positive acute phase reactant in cats.
The new cat LRG1 assay joins SPARCL based monkey and human LRG1 assays in the Life Diagnostics lineup.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
Life Diagnostics adds two new SPARCL™ alpha-fetoprotein assays to their lineup
Life Diagnostics, Inc. adds two new alpha-fetoprotein (AFP) assays to its extensive lineup of SPARCL assays. The new assays were developed for cats (AFP-SP-8) and dogs (AFP-SP-4).
Serum alpha-fetoprotein (AFP) levels are elevated in humans and dogs suffering from liver cancer, liver disease and some non-hepatic cancers, allowing AFP to be used as a biomarker to monitor disease progression.
- Life Diagnostics researchers found levels as high as 500 ng/ml in serum of cats with cancer. Levels in serum from healthy cats were undetectable.
- Serum alpha-fetoprotein (AFP) levels are elevated in dogs suffering from liver cancer, liver disease and some non-hepatic cancers. Levels decrease after surgical removal of tumors and during cancer remission.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
Life Diagnostics adds a new SPARCL™ thymidine kinase assay to their lineup
Life Diagnostics, Inc. adds a new thymidine kinase 1 (TK1) assay to its extensive lineup of SPARCL assays. The new assay was developed for cows (TK1-SP-11), and joins TK1 SPARCL assays previously developed for cats (TK1-SP-8), dogs (TK1-SP-4), and humans (TK1-SP-20).
Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis. Its expression levels increase in tissues such as tumors that are proliferating. Upon tumor cell death and lysis, TK1 is released into serum.
- In cows, TK1 enzyme activity has been associated with leukosis.
- In cats, TK1 is a potential biomarker for lymphoma.
- In dogs, it provides a biomarker for lymphoma and mammary tumors.
- In humans, TK1 provides a biomarker for tumor growth and metastasis.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
Life Diagnostics adds three new SPARCL™ assays for human cancer research
Life Diagnostics, Inc. adds three new human cancer research assays to its extensive lineup of SPARCL assays. The assays were developed for CYFRA 21-1 (CYFR-SP-20), CA 19-9 (CA19-SP-20) and CA 72-4 (CA72-SP-20).
All three kits are for research use only.
- CYFRA 21-1 is a fragment of cytokeratin 19 produced by proteolysis in malignant tissues, and is used as a serum biomarker for some types of cancer.
- CA 19-9 is a carbohydrate antigen found on the MUC1 protein that is expressed and shed from some tumor cells. Increased serum levels of CA 19-9 may be associated with pancreatic and gastrointestinal cancer.
- CA 72-4 is a glycoprotein that is expressed on the surface of cancer cells. Increased levels of CA 72-4 are found in the serum of some cancer patients.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
Life Diagnostics adds three new SPARCL™ assays to their lineup
Life Diagnostics, Inc. adds three new thymidine kinase 1 (TK1) assays to its lineup of over 85 SPARCL assays. The assays were developed for cats (TK1-SP-8), dogs (TK1-SP-4), and humans (TK1-SP-20).
Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis. Its expression levels increase in tissues such as tumors that are proliferating. Upon tumor cell death and lysis, TK1 is released into
serum.
- In cats, TK1 is a potential biomarker for lymphoma.
- In dogs, it provides a biomarker for lymphoma and mammary tumors.
- In humans, TK1 provides a biomarker for tumor growth and metastasis.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.
Life Diagnostics adds a new SPARCL™ assay to their lineup
Life Diagnostics, Inc. adds a new cat C-reactive protein (CRP) assay to its lineup of over 85 SPARCL assays.
In most mammals, CRP (C-reactive protein) is a positive acute phase protein that is elevated in serum following injury, infection and disease. In cats, a three-fold increase in CRP levels is reported after retrovirus infection.
In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.